Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.

Dharmesh Gopalakrishnan,Katharine Collier,Joseph J. Park,Jacob P Zaemes,Elaine Tat Lam,Sabah Alaklabi,Ellen Jaeger,Rahul Atul Parikh,Pedro C. Barata,Eric C. Kauffman,Michael B. Atkins,Ajjai Alva,Yuanquan Yang,Saby George

Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.

2021

Dharmesh Gopalakrishnan
Katharine Collier
Joseph J. Park
Jacob P Zaemes
Elaine Tat Lam
Sabah Alaklabi
Ellen Jaeger
Rahul Atul Parikh
Pedro C. Barata
Eric C. Kauffman
Michael B. Atkins
Ajjai Alva
Yuanquan Yang
Saby George

4568Background: Advanced sRCC is an aggressive disease with limited responsiveness to chemotherapy and VEGF-targeted therapies. Subgroup analyses from randomized trials showed improved outcomes wit...

Keywords:

aggressive disease
Medicine
Internal medicine
Sarcomatoid Renal Cell Carcinoma
Chemotherapy
Randomized controlled trial
Oncology
multicenter study
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations